1H-吲哚-5-乙胺 | 21005-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1H-吲哚-5-乙胺
• 中文别名: [2-(1H-吲哚-5-基)乙基]胺；2-(1H-吲哚-5-基)乙胺
• 英文名称: 2-(1H-indol-5-yl)ethan-1-amine
• 英文别名: 2-(1H-Indol-5-yl)ethanamine
• CAS: 21005-60-7
• 化学式: C₁₀H₁₂N₂
• mdl: MFCD08448752
• 分子量: 160.219
• InChiKey: ALEWOQWOFUSKHR-UHFFFAOYSA-N

物化性质

• 沸点：
  342.5±17.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1H-吲哚-5-乙胺 以 二氯甲烷 、 苯 为溶剂， 反应 1.83h， 生成 5-(2-acetamidoethyl)-N,N-dimethylindole-3-methanamine
  参考文献：
  名称：

  Aminoethyl-substituted indole-3-acetic acids for the preparation of tagged and carrier-linked auxin

  摘要：

  Indole-3-acetic acid is an indispensable hormone (auxin) in plants and an important metabolite in humans, animals, and microorganisms. Here we introduce its 5- and 6-(2-aminoethyl)-derivatives for use in the design of novel research tools, such as immobilized and carrier-linked forms of indole-3-acetic acid and its conjugates with biochemical tags or biocompatible molecular probes. The aliphatic nitrogens of 5- and 6-(2-aminoethyl)indole were acetylated and the products were converted to the corresponding 3-(N,N-dimethylamino)methyl derivatives (gramines). These were reacted with cyanide. Saponification of the resulting acetonitriles was accompanied by N-deprotection to yield 5- and 6-(2-aminoethyl)indole-3-acetic acids. The latter were chemically stable and could be linked, via their amino groups, and without prior protection of their carboxyl moieties, to bovine serum albumin and to biotin, including appropriate spacer modules. One of the protein conjugates was used to elicit the formation of monoclonal antibodies, which were evaluated using the biotin conjugates in an enzyme-linked immunosorbent assay employing streptavidin-coupled alkaline phosphatase, and thus shown to recognize predominantly the indole-3-acetic acid moiety. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.02.046
• 作为产物：
  描述：

  5-吲哚甲醛 在 sodium tetrahydroborate 、 ammonium acetate 、 铁粉 、 氯化铵 作用下， 以 甲醇 、 水 、 异丙醇 为溶剂， 反应 2.75h， 生成 1H-吲哚-5-乙胺
  参考文献：
  名称：

  4-Indolyl- N -hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo

  摘要：

  A series of 4,5-indolyl-N-hydroxyphenylacrylamides, as HDAC inhibitors, has been synthesized and evaluated in vitro and in vivo. 4-Indolyl compounds 13 and 17 functions as potent inhibitors of HDAC1 (IC50 1.28 nM and 134 nM) and HDAC 2 (IC50 0.90 and 0.53 nM). N-Hydroxy-3-{4-[2-(1H-indo1-4-y1)-ethylsulfamoyl]-phenyl}-actylamide (13) inhibited the human cancer cell growth of PC3, A549, MDA-MB-231 and AsPC-1 with a GI(50) of 0.14, 0.25, 0.32, and 0.24 mu M, respectively. In in vivo evaluations bearing prostate PC3 xenografts nude mice model, compound 13 suppressed tumor growth with a tumor growth inhibition (TGI) of 62.2%. Immunohistochemistry of protein expressions, in PC-3 xenograft model indicated elevated acetyl-histone 3 and prominently inhibited HDAC2 protein expressions. Therefore, compound 13 could be a suitable lead for further investigation and the development of selective HDAC 2 inhibitors as potent anti-cancer compounds. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.03.079

文献信息

• [EN] PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DES PGE2
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018210988A1

  公开（公告）日：2018-11-22

  The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式(I)的嘧啶衍生物，其中(R1)n，R3，R4a，R4b，R5a，R5b和Ar1如描述中所述，以及它们通过调节免疫反应，包括肿瘤中免疫系统的再激活，用于治疗癌症。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(II)，及其作为药物的使用，其制备，药用可接受的盐，及其作为药物的使用，以及包含式(I)中一个或多个化合物的药物组合物，尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
• [EN] HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY<br/>[FR] COMPOSES HETEROCYCLIQUES, PROCEDES DE PRODUCTION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS UN TRAITEMENT
  申请人：AFFINIUM PHARM INC

  公开号：WO2004052890A1

  公开（公告）日：2004-06-24

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  在某种程度上，本发明涉及公式（I）的抗菌化合物，其中A是一个双环杂芳基环或三环环，R2是一个杂环残基；L是一个键，或者L是烷基，烯基或环烷基。
• [EN] BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION<br/>[FR] LIGANDS DE BROMODOMAINE POUVANT SE DIMÉRISER DANS UNE SOLUTION AQUEUSE
  申请人：COFERON INC

  公开号：WO2015081280A1

  公开（公告）日：2015-06-04

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本文描述的是一种单体，当与水性介质中的一个、两个、三个或更多其他单体接触时，能够形成具有生物学用途的多聚体。在一个方面，这些单体可能能够在水性介质中（例如体内）与另一个单体结合，形成一个多聚体（例如二聚体）。考虑到的单体可能包括一个配体基团、一个连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素相互结合，因此可以同时调节一个或多个生物分子，例如，调节蛋白质上的两个或更多结合结构域或不同蛋白质上的结合结构域。
• Piperidinyl indoles for migraine treatment
  申请人：Glaxo Group Limited

  公开号：US05036078A1

  公开（公告）日：1991-07-30

  Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents C.sub.1-6 alkyl; R.sub.2 represents H or C.sub.1-6 alkyl; R.sub.3 represents H or C.sub.1-3 alkyl; and pharmaceutically acceptable salts and solvates (for example hydrates) thereof. The compounds are indicated as useful for the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders. Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.

  公开了式子（I）的化合物 ##STR1## 其中R.sub.1代表C.sub.1-6烷基；R.sub.2代表H或C.sub.1-6烷基；R.sub.3代表H或C.sub.1-3烷基；以及其药学上可接受的盐和溶剂化物（例如水合物）。这些化合物被指示用于治疗偏头痛、集群头痛、慢性阵发性半侧头痛和与血管障碍相关的头痛。还公开了它们的制备过程和中间体，以及含有它们的制药组合物。
• Compositions comprising multiple bioactive agents, and methods of using the same
  申请人：Berman M. Judd

  公开号：US20060142265A1

  公开（公告）日：2006-06-29

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及含有FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分，本发明涉及含有I-III式化合物和至少一种其他抗菌剂的抗菌组合物。